Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The globally widespread single-gene disorders β-thalassemia and sickle cell anemia (SCA) can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). HSCT treatment of thalassemia has substantially improved over the last two decades, with advancements in preventive strategies, control of transplant-related complications, and preparative regimens. A risk class-based transplantation approach results in disease-free survival probabilities of 90%, 84%, and 78% for class 1, 2, and 3 thalassemia patients, respectively. Because of disease advancement, adult thalassemia patients have a higher risk for transplant-related toxicity and a 65% cure rate. Patients without matched donors could benefit from haploidentical mother-to-child transplantation. There is a high cure rate for children with SCA who receive HSCT following myeloablative conditioning protocols. Novel non-myeloablative transplantation protocols could make HSCT available to adult SCA patients who were previously excluded from allogeneic stem cell transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bone Marrow Transplantation in Patients with Thalassemia
Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., Politi, P., Durazzi, S. M. T., Muretto, P., & Albertini, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220701 · Cited by 636 · cited 1×
“The influence of pretransplant characteristics on the outcome of transplantation was analyzed in 161 patients ,17 yr of age, who were all treated with exactly the same regimen (Storb et al. 1977; Lucarelli et al. 1990).”
MethodSelf-citationLong-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.-P., Yakouben, K., Thuret, I., Bordigoni, P., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079665 · Cited by 515
Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease
Hsieh, M. M., Kang, E. M., Fitzhugh, C. D., Link, M. B., Bolan, C. D., Kurlander, R., Childs, R. W., Rodgers, G. P., Powell, J. D., & Tisdale, J. F. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904971 · Cited by 455
World Distribution, Population Genetics, and Health Burden of the Hemoglobinopathies
Williams, T. N., & Weatherall, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011692 · Cited by 430
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease
Locatelli, F. (2003) · Blood · doi:10.1182/blood-2002-07-2090 · Cited by 386 · cited 1×
“…88% Class 3: 87% Adult: 66% Class 1–2: 85% Class 3: 82% Adult: 62% Lucarelli et al. 2008 68 MUD 79.3% 40% La Nasa et al. 2005a 33 Cord blood 100% 79% Locatelli et al. 2003 70 MSD/MRD 83% 73% Ghavamzadeh et al. 1997 49 Related: 28 Unrelated: 21 89% (all patients) Related: 82% Unrelated: 71%…”
InfluentialWalters, M. C., Storb, R. F., Patience, M., Leisenring, W. M., Taylor, T., Sanders, J. E., Buchanan, G. E., Rogers, Z. R., Dinndorf, P. A., Davies, S. C., et al. (2000) · PubMed · doi:10.1182/blood.v95.6.1918 · Cited by 361
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia
Walters, M. C., Patience, M., Leisenring, W., Rogers, Z. R., Aquino, V. M., Buchanan, G. R., Roberts, I. A. G., Yeager, A. M., Hsu, L., Adamkiewicz, T., et al. (2001) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2001.v7.pm11787529 · Cited by 324 · cited 1×
“Walters et al. (2001) observed stable MC in 13 out of 50 patients (26”
BackgroundIannone, R., Casella, J. F., Fuchs, E. J., Chen, A. R., Jones, R. J., Woolfrey, A., Amylon, M., Sullivan, K. M., Storb, R. F., & Walters, M. C. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(03)00192-7 · Cited by 269 · cited 1×
“In a retrospective multicenter series, Iannone et al. (2003) described a non-myeloablative HSCT approach in six pediatric patients with SCD and one with thalassemia.”
BackgroundVermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhooge, C., Benoit, Y., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701291 · Cited by 260 · cited 1×
“The results of transplantation might be even better if HSCT were performed in children before the development of irreversible sickle vasculopathy-related complications (Vermylen et al. 1998; Lucarelli et al. 2011).”
BackgroundAPLASTIC ANAEMIA TREATED BY MARROW TRANSPLANTATION
Donnall Thomas, E., Storb, R., Fefer, A., Slichter, S., Bryant, J., Dean Buckner, C., Neiman, P., Clift, R., Funk, D., & Lerner, K. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90292-9 · Cited by 250 · cited 1×
“Cyclophosphamide (CY) is a well-established agent for providing adequate immunosuppression for allogeneic engraftment (Thomas et al. 1972; Storb et al. 1991).”
Background
Cited by
Items 101–164 of 164
Mauriello, A., Giacobbi, E., Saggini, A., Isgrò, A., Facchetti, S., & Anemona, L. (2017) · Pathology · doi:10.1016/j.pathol.2016.11.010 · Cited by 3
Xu, J., Junyu, Z., Tian, X., Qixin, S., Xu, J., Huang, Y., He, Y., Huang, Z., & Wu, B. (2017) · Transplantation · doi:10.1097/tp.0000000000001832 · Cited by 3
“[2-4] The long-term survival of patients after HSCT has improved over the past decade, and the”
BackgroundTreatment of Genetic Diseases: Current Trends in the Development of Biomedical Cell Products
Анатольевна, Р. О., Vodyakova, M. A., Melnikova, E. V., & Меркулов, В. А. (2019) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2019-19-4-225-232 · Cited by 3
Darrigo, L. G., Costa, T. C. D. M., Vieira, A. K., Albino, C. D., Barros, G. M. N., Garcia, J. L., Fortunato, L. R., Santos, F. L. S., Fonseca, G., Cunha, R., et al. (2021) · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY · doi:10.46765/2675-374x.2021v2n4p132 · Cited by 4
Association of Beta-Thalassaemia and Hypogonadotropic Hypogonadism
Vidal, À., & Dhakal, C. (2022) · Case Reports in Obstetrics and Gynecology · doi:10.1155/2022/4655249 · Cited by 4
“In some cases, bone marrow transplants are not sexmatched [5, 6].”
BackgroundFinotti, A., Borgatti, M., Bianchi, N., Zuccato, C., Lampronti, I., & Gambari, R. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1135793 · Cited by 6
“lassemia patients lack a suitable donor.[37] In this case, HLA-matched unrelated donors may be considered for BMT.”
BackgroundMechanistic and Translational Advances Using iPSC-Derived Blood Cells
Thom, C. S., Chou, S. T., & French, D. L. (2020) · Journal of Experimental Pathology · doi:10.33696/pathology.1.010 · Cited by 3
“Allogeneic hematopoietic stem cell transplant is already a first-line treatment to cure SCD and thalassemia in some parts of the world [34], but autologous transplant of gene-corrected cells would eliminate risks of graft versus host disease and graft rejection.”
BackgroundObeagu, E. I. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003619 · Cited by 3
“In SCD, these adhesion molecules are often overexpressed due to the chronic inflammatory state induced by sickled cells and their interaction with the endothelial cells [ 5 , 6 ] . sRBCs themselves also play a crucial role in promoting the expression of adhesion molecules.”
Folarin, M., Al-Zubaidi, H., Moore, E., Eze, U. A., & Palanisamy, N. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.09.023 · Cited by 2
Segura, E., Hart, K. L., Fernandez, B. C., Brown, D., Tam, K., Garcia, A. G., Seigneurbieux, E., Li, K., Mulumba, C., Blakely, E., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102362 · Cited by 2
Adanır, A. S., Taşkıran, G., Koparan, C., & Özatalay, E. (2017) · Güncel Pediatri · doi:10.4274/jcp.2017.0024 · Cited by 2
Isgrò, A., Sodani, P., Marziali, M., Gaziev, J., Fraboni, D., Paciaroni, K., Gallucci, C., Angelis, G. D., Alfieri, C., Ribersani, M., et al. (2014) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2014.054 · Cited by 2
Self-citationCrazzolara, R., Kropshofer, G., Steurer, M., Sopper, S., & Schwinger, W. (2017) · Journal of Visualized Experiments · doi:10.3791/56002 · Cited by 2
The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment
Lai, M. I., & Ahmed, N. H. M. (2022) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x23666230123140926 · Cited by 4
Targeting the bone marrow niche in hemoglobinopathies
Carlesso, N. (2020) · Blood · doi:10.1182/blood.2020006305 · Cited by 2
Khaled, W., El-Kaffas, A., Elbarky, A. M., Sharawy, F., & Hablas, N. M. (2024) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_102_23 · Cited by 1
The DKMS Access to Transplantation program: addressing barriers to HSCT
Landwehr, R., Bernas, S. N., Neujahr, E., & Schmidt, A. H. (2026) · Blood Global Hematology · doi:10.1016/j.bglo.2026.100067 · Cited by 1
Alquadan, O., Deebaja, R., Gupte, A., & Al‐Antary, E. T. (2026) · Pediatric Annals · doi:10.3928/19382359-20260629-01 · Cited by 1
Photopheresis long after the initiation of chronic graft versus host in a child
Uygun, V., Daloğlu, H., Karasu, G., & Yeşilipek, A. (2014) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2014.08.016 · Cited by 1
“Allogeneic HSCT is the only curative therapeutic option in patients with beta thalassemia major [7,8].”
BackgroundEpigenetic gene regulation and stem cell function
Benyoucef, A., & Brand, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-799958-6.00007-x · Cited by 2
Kucine, N., & Giardina, P. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.00005-2 · Cited by 1
Chumchuen, S., Sripichai, O., Jearawiriyapaisarn, N., Fucharoen, S., & Peerapittayamongkol, C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281059 · Cited by 2
“With several constraints such as applicable to the relatively young age patients and suitable HLA-matched donors make this curative approach unavailable for most β-thalassemia patients [8].”
BackgroundTimothee, B. M. V., Du, J., Ren, Y., He, Y., Ruan, Y., Liu, X., Chen, L., Wen, J., Ding, R., Yu, L., et al. (2023) · Acta Haematologica · doi:10.1159/000532086 · Cited by 1
Haematopoietic Stem Cell Transplantation in Thalassaemia Major: A Narrative Review
Yousuf, R., Jahan, D., Sinha, S., & Haque, M. (2023) · Advances in Human Biology · doi:10.4103/aihb.aihb_104_23 · Cited by 1
Thalassemia: Molecular Bases, Recent Advances in Diagnosis and Treatment Challenges
de Macêdo, A. C., Barros, L. A., Lima, D. P. D. S., & Oshiro, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00043-3 · Cited by 1
Avila, C. D., Martinez, P. A., Sendi, P. R., Silva, J. R. G., Maher, O. M., & Totapally, B. (2024) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2024.2378282 · Cited by 2
WGCNA and LASSO regression-based selection and validation of microRNA biomarkers of β-thalassemia
Yang, F., Shi, L., Su, S., Li, Y., Cheng, H., Liang, Z., Pang, L., & Lai, K. (2025) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2025.102957 · Cited by 1
Advances in Stem Cell Therapies
Lufkin, T., & Sng, J. (2012) · InTech eBooks · doi:10.5772/55061 · Cited by 1
“HSCT has also been utilized to cure other diseases including sickle cell anemia, acquired aplastic anemia and thalassemia [62, 63].”
BackgroundStem Cell Applications: An Overview
Eridani, S. (2014) · Springer eBooks · doi:10.1007/978-3-642-45207-9_1 · Cited by 1
“high dose of busulfan and suppression of the immune system by administration of cyclophosphamide [ 57 ].”
BackgroundHematopoietic Stem-Cell Transplantation for Sickle Cell Disease
Woodard, P. (2006) · CRC Press eBooks · doi:10.3109/9780849358807-24 · Cited by 1
What Is the Relevance of Murburn Concept in Thalassemia and Respiratory Diseases?
Manoj, K. M. (2023) · Thalassemia Reports · doi:10.3390/thalassrep13020013 · Cited by 1
Basics of Stem Cell Transplant
Sharma, S. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-5802-1_2 · Cited by 3
Jarduli, L. R. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2018.tde-27062018-080953 · Cited by 2
de Azevedo, J. T. C. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2020.tde-14112019-123958 · Cited by 2
Han, N., Li, Y., Ouyang, W., Dong, G., Guo, H., Chen, Y., Huang, Y., Zeng, X., Zou, H., He, J., et al. (2023) · medRxiv · doi:10.1101/2023.03.21.23287513 · Cited by 1
Beta Talasemi Majorlu Hastalarda Hematopoetik Kök Hücre Transplantasyonu
Yesilipek, M. A. (2014) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.22596
Orak Hücre Anemisinde Hematopoetik Kök Hücre Transplantasyonu
Tanyeli, A. (2014) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.43132
Gene Therapy for Haemoglobinopathies
Goodman, M., & Malik, P. (2016) · Wiley eBooks · doi:10.1002/9780470015902.a0025347
Allogeneic Hematopoietic Cell Transplant in β-Thalassemia Major
Abutalib, S. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-30352-9_6
Or‐Geva, N., & Reisner, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-54310-9_2
Sickle Cell Anemia: A review on the most severe form of Sickle Cell Disease
Paredes, M. B., & Sulen, M. E. (2019) · Bionatura · doi:10.21931/rb/cs/2019.02.01.19
Gene Therapy: Principles and Clinical Potential
Buckley, S. M. K., & David, A. L. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108564434.053
Devaraju, P., Kaliyaperumal, D., & Madhavan, T. (2019) · Introduction to Basics of Pharmacology and Toxicology · doi:10.1007/978-981-32-9779-1_24
Sokolova, A. V., Тимонина, Н. А., Васильевна, К. В., Krivoi, I. I., Skripkina, N. S., Каминская, Е. В., & Mikhailov, V. M. (2020) · Genes and Cells · doi:10.23868/202003005
Introductory Chapter: β-Thalassemia
Zakaria, M. M., & Hassan, T. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90946 · Cited by 1
“Currently, allogeneic stem cell transplant [allo-SCT] remains the only curative option for the majority of patients with β-thalassemia major before development of iron overload complications [22].”
BackgroundQuinn, C. T. (2013) · The Hematologist · doi:10.1182/hem.v10.5.1038
Cienkusz, M., Lejman, M., Dąbrowska-Leonik, N., Choma, M., & Drabko, K. A. (2020) · Central European Journal of Immunology · doi:10.5114/ceji.2020.94786
“In the literature, reports on donor lymphocyte infusion at unstable mixed chimerism after allogeneic stem cells transplantation for non-malignant disorders mainly consider patients with thalassemia, sickle cell anemia, or hemoglobinopathies [20-22].”
BackgroundHematopoietic stem cell transplantation for non-malignant hematological disorders
Formánková, R., & Starý, J. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.075 · Cited by 1
Chappell, H., & Gallicchio, V. S. (2022) · Journal Of Stem Cell Research · doi:10.52793/jscr.2022.3(1)-03
“However, 10 out of the 11 patients survived without sickle cell disease with full donor chimerism in lymphoid and myeloid lineages [25].”
BackgroundMethodInfluentialQidwai, T. (2021) · Springer eBooks · doi:10.1007/978-981-33-4761-8_4
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMOGLOBINOPATHIES
Costa, T. C. D. M., Darrigo, L. G., Vieira, A. K., Albino, C. D., Barros, G. M. N., Garcia, J. L., Fortunato, L. R., Santos, F. L. S., Santis, G. C. D., Fonseca, G., et al. (2023) · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY · doi:10.46765/2675-374x.2023v4n1p183
Case Report of a Child with Beta Thalassemia Major in a Tribal Region of India
Neha, C., Narayan, P., Mahesh, N., & Manisha, S. (2023) · Journal of Child Adult Vaccines and Immunology · doi:10.29328/journal.jcavi.1001011
“Bone marrow or hematopoietic stem cell allogeneic transplantation [10] after 10-12 years in a child increases the life expectancy.”
BackgroundLiu, R., & Chen, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3622742/v1
Conventional and Innovative Molecular Approaches Developed for Treating Hemoglobinopathies
Miliotou, Α. N., Georgiou‐Siafis, S. K., Vlachaki, E., Pappas, I. S., Vizirianakis, I. S., Tsiftsoglou, A. S., & Papadopoulou, L. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00025-1
Salama, R., Elhawary, E. E., Ziada, D. H., El-Shanshory, M. R., & El-Kaffas, A. (2023) · The Egyptian Journal of Haematology · doi:10.4103/ejh.ejh_36_23
ПРОБЛЕМА ГЕМОГЛОБИНОПАТИЙ В МИРЕ И СОВРЕМЕННЫЕ МЕТОДЫ БОРЬБЫ С НИМИ
Меджнун, Ш. О. Б., & Рена, Ф. К. М. (2024) · Международная научно-практическая конференция «Актуальные проблемы науки и образования в условиях современных вызовов» · doi:10.58351/240307.2024.98.86.002
Singh, K., Ansari, N. A., Ansari, M. S., & Bhat, M. Y. (2024) · Springer eBooks · doi:10.1007/978-981-97-6001-5_7
Generation and clinical applications of stem cells in regenerative medicines
Chattopadhyay, R. (2024) · Journal of Applied and Natural Science · doi:10.31018/jans.v16i4.5886
Mercan, T. K., Arıkan, Y., Kurtoğlu, E., & Keser, İ. (2025) · Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi · doi:10.47572/muskutd.1658534
Wu, S., Lu, W., Xie, A., Wang, J., Zeng, W., Chen, C., Wu, N., Ye, J., Zou, Z., Li, L., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04955-0
“Over the past decades, allogeneic hematopoietic stem cell transplantation has remained a critical therapeutic approach for various malignant and non-malignant hematological disorders [39, 40].”
Azeez, A. H., Vallabhaneni, H., Theyver, A., Kodamanchili, S. P. D. R., Dohadwala, T. K., Rangrej, V., Leyfman, Y., & Park, C. H. (2026) · Encyclopedia · doi:10.3390/encyclopedia6060131
ElGohary, G. M., Alsharif, M., Fakih, R. O. E., Lamine, C. B., Shaheen, M., & Aljurf, M. D. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02982-2
“Fertility data, though promising for NMA, are still needed for longer follow-up to fully characterize reproductive outcomes across all age groups [2, 8, 23, 27, 28].”
InfluentialAl‐Jefri, A., Siddiqui, K. S., Sultan, M. A., AlOtaibi, S., Khan, S. J., AlAnazi, A., Ayas, M. F., Alsaedi, H. S., Al-Musa, A., Saleh, M. A., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70455
Radad, K., Mokhtar, M., Eid, R. A., Al-Shraim, M. M., Omar, H., & Ghafar, S. K. A. (2026) · Ultrastructural Pathology · doi:10.1080/01913123.2026.2739246
Metadata
- Authors
- Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J.
- Affiliations
- University of Rome Tor Vergata (IT)
- Corresponding author
- Lucarelli, G.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-04-04
- Volume
- 2
- Issue
- 5
- Pages
- a011825-a011825
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3331690
- OpenAlex
- W2113456470
- Cited by
- 166
- References
- 50
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 14 · 2023: 16 · 2022: 12 · 2021: 14 · 2020: 14 · 2019: 12 · 2018: 10 · 2017: 11 · 2016: 12 · 2015: 10 · 2014: 16 · 2013: 6 · 2012: 2
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hematopoietic stem cell transplantation, thalassemia, sickle cell disease, allogeneic transplantation, risk stratification, transplant toxicity, haploidentical transplantation, myeloablative conditioning, nonmyeloablative conditioning, disease-free survival
- MeSH terms
- Adult, Anemia, Sickle Cell, Graft vs Host Disease, Humans, Thalassemia, Hematopoietic Stem Cell Transplantation, Living Donors, Myeloablative Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.